Top Institutions in Ophthalmology and Biomedical Engineering
Leading institutions combine expertise in ophthalmology, molecular biology, and biomedical engineering to develop aptamer-based therapeutics and biosensors integrated into contact lenses. Their research includes aptamer design, hydrogel biomaterials, ocular pharmacokinetics, and clinical translation of novel drug delivery systems.
-
#1
Massachusetts Institute of Technology (MIT) - Koch Institute for Integrative Cancer Research
Cambridge, MA
MIT leads in aptamer engineering and biomaterials research, pioneering hydrogel-based drug delivery systems and biosensors, including ocular applications. Their interdisciplinary approach integrates molecular design with advanced materials for targeted and controlled drug release.
-
#2
Johns Hopkins University - Wilmer Eye Institute
Baltimore, MD
Wilmer Eye Institute is a leader in translational ophthalmic research and clinical trials, with extensive expertise in ocular drug delivery systems and novel therapeutics including aptamer-based treatments for retinal diseases.
-
#3
Stanford University - Department of Ophthalmology and Institute for Stem Cell Biology and Regenerative Medicine
Stanford, CA
Stanford excels in molecular aptamer research and regenerative ophthalmology, developing novel biomolecular tools for ocular disease diagnostics and therapeutics, including aptamer-based biosensors integrated with contact lenses.
-
#4
University of California, San Diego (UCSD) - Jacobs School of Engineering and Shiley Eye Institute
La Jolla, CA
UCSD integrates engineering and clinical ophthalmology to innovate in drug delivery platforms, including aptamer-functionalized hydrogels and contact lenses, with a focus on translational applications for chronic ocular diseases.
-
#5
Harvard Medical School - Schepens Eye Research Institute
Boston, MA
Schepens Eye Research Institute is renowned for its molecular ophthalmology research, including aptamer therapeutics and innovative ocular drug delivery methods, contributing to FDA-approved aptamer drugs and novel contact lens technologies.
